Visual complexity in human-machine interaction = Visuelle Komplexität in der Mensch-Maschine Interaktion

Visuelle Komplexität wird oft als der Grad an Detail oder Verworrenheit in einem Bild definiert (Snodgrass & Vanderwart, 1980). Diese hat Einfluss auf viele Bereiche des menschlichen Lebens, darunter auch solche, die die Interaktion mit Technologie invol-vieren. So wurden Effekte visueller Komplexität etwa im Straßenverkehr (Edquist et al., 2012; Mace & Pollack, 1983) oder bei der Interaktion mit Software (Alemerien & Magel, 2014) oder Webseiten (Deng & Poole, 2010; Tuch et al., 2011) nachgewie-sen. Obwohl die Erforschung visueller Komplexität bereits bis auf die Gestaltpsycho-logen zurückgeht, welche etwa mit dem Gestaltprinzip der Prägnanz die Bedeutung von Simplizität und Komplexität im Wahrnehmungsprozess verankerten (Koffka, 1935; Wertheimer, 1923), sind weder die Einflussfaktoren visueller Komplexität, noch die Zusammenhänge mit Blickbewegungen oder mentaler Beanspruchung bisher ab-schließend erforscht. Diese Punkte adressiert die vorliegende Arbeit mithilfe von vier empirischen Forschungsarbeiten. In Studie 1 wird anhand der Komplexität von Videos in Leitwarten sowie der Effekte auf subjektive, physiologische und Leistungsparameter mentaler Beanspruchung die Bedeutung des Konstruktes im Bereich der Mensch-Maschine Interaktion untersucht. Studie 2 betrachtet die dimensionale Struktur und die Bedeutung verschiedener Ein-flussfaktoren visueller Komplexität genauer, wobei unterschiedliches Stimulusmaterial genutzt wird. In Studie 3 werden mithilfe eines experimentellen Ansatzes die Auswir-kungen von Einflussfaktoren visueller Komplexität auf subjektive Bewertungen sowie eine Auswahl okularer Parameter untersucht. Als Stimuli dienen dabei einfache, schwarz-weiße Formenmuster. Zudem werden verschiedene computationale und oku-lare Parameter genutzt, um anhand dieser Komplexitätsbewertungen vorherzusagen. Dieser Ansatz wird in Studie 4 auf Screenshots von Webseiten übertragen, um die Aussagekraft in einem anwendungsnahen Bereich zu untersuchen. Neben vorangegangenen Forschungsarbeiten legen insbesondere die gefundenen Zusammenhänge mit mentaler Beanspruchung nahe, dass visuelle Komplexität ein relevantes Konstrukt im Bereich der Mensch-Maschine Interaktion darstellt. Dabei haben insbesondere quantitative und strukturelle, aber potentiell auch weitere Aspekte Einfluss auf die Bewertung visueller Komplexität sowie auf das Blickverhalten der Be-trachter. Die gewonnenen Ergebnisse erlauben darüber hinaus Rückschlüsse auf die Zusammenhänge mit computationalen Maßen, welche in Kombination mit okularen Parametern gut für die Vorhersage von Komplexitätsbewertungen geeignet sind. Die Erkenntnisse aus den durchgeführten Studien werden im Kontext vorheriger For-schungsarbeiten diskutiert. Daraus wird ein integratives Forschungsmodell visueller Komplexität in der Mensch-Maschine-Interaktion abgeleitet

The THO complex as a key mRNP biogenesis factor in development and cell differentiation

The THO complex is a key component in the co-transcriptional formation of messenger ribonucleoparticles that are competent to be exported from the nucleus, yet its precise function is unknown. A recent study in BMC Biology on the role of the THOC5 subunit in cell physiology and mouse development provides new clues to the role of the THO complex in cell differentiation

Upgrade of the ultracold neutron source at the pulsed reactor TRIGA Mainz

The performance of the upgraded solid deuterium ultracold neutron source at the pulsed reactor TRIGA Mainz is described. The current configuration stage comprises the installation of a He liquefier to run UCN experiments over long-term periods, the use of stainless steel neutron guides with improved transmission as well as sputter-coated non-magnetic $^{58}$NiMo alloy at the inside walls of the thermal bridge and the converter cup. The UCN yield was measured in a `standard' UCN storage bottle (stainless steel) with a volume of 32 litres outside the biological shield at the experimental area yielding UCN densities of 8.5 /cm$^3$; an increase by a factor of 3.5 compared to the former setup. The measured UCN storage curve is in good agreement with the predictions from a Monte Carlo simulation developed to model the source. The growth and formation of the solid deuterium converter during freeze-out are affected by the ortho/para ratio of the H$_2$ premoderator.Comment: 12 pages, 7 figure

Colorectal cancer in young patients : a case report

Resumo não disponíve

VIPP2 interacts with VIPP1 and HSP22E/F at chloroplast membranes and modulates a retrograde signal for HSP22E/F gene expression

VIPP proteins aid thylakoid biogenesis and membrane maintenance in cyanobacteria, algae, and plants. Some members of the Chlorophyceae contain two VIPP paralogs termed VIPP1 and VIPP2, which originate from an early gene duplication event during the evolution of green algae. VIPP2 is barely expressed under nonstress conditions but accumulates in cells exposed to high light intensities or H2O2, during recovery from heat stress, and in mutants with defective integration (alb3.1) or translocation (secA) of thylakoid membrane proteins. Recombinant VIPP2 forms rod-like structures in vitro and shows a strong affinity for phosphatidylinositol phosphate. Under stress conditions, >70% of VIPP2 is present in membrane fractions and localizes to chloroplast membranes. A vipp2 knock-out mutant displays no growth phenotypes and no defects in the biogenesis or repair of photosystem II. However, after exposure to high light intensities, the vipp2 mutant accumulates less HSP22E/F and more LHCSR3 protein and transcript. This suggests that VIPP2 modulates a retrograde signal for the expression of nuclear genes HSP22E/F and LHCSR3. Immunoprecipitation of VIPP2 from solubilized cells and membrane-enriched fractions revealed major interactions with VIPP1 and minor interactions with HSP22E/F. Our data support a distinct role of VIPP2 in sensing and coping with chloroplast membrane stress

Decreasing trends of particle number and black carbon mass concentrations at 16 observational sites in Germany from 2009 to 2018

Anthropogenic emissions are dominant contributors to air pollution. Consequently, mitigation policies have been attempted since the 1990s in Europe to reduce pollution by anthropogenic emissions. To evaluate the effectiveness of these mitigation policies, the German Ultrafine Aerosol Network (GUAN) was established in 2008, focusing on black carbon (BC) and sub-micrometre aerosol particles. In this study, long-term trends of atmospheric particle number concentrations (PNCs) and equivalent BC (eBC) mass concentration over a 10-year period (2009-2018) were determined for 16 GUAN sites ranging from roadside to high Alpine environments. Overall, statistically significant decreasing trends are found for most of these parameters and environments in Germany. The annual relative slope of eBC mass concentration varies between-13.1% and-1.7% per year. The slopes of the PNCs vary from-17.2% to-1.7 %,-7.8% to-1.1 %, and-11.1% to-1.2% per year for 10-30, 30-200, and 200-800 nm size ranges, respectively. The reductions in various anthropogenic emissions are found to be the dominant factors responsible for the decreasing trends of eBC mass concentration and PNCs. The diurnal and seasonal variations in the trends clearly show the effects of the mitigation policies for road transport and residential emissions. The influences of other factors such as air masses, precipitation, and temperature were also examined and found to be less important or negligible. This study proves that a combination of emission mitigation policies can effectively improve the air quality on large spatial scales. It also suggests that a long-term aerosol measurement network at multi-type sites is an efficient and necessary tool for evaluating emission mitigation policies. © 2020 Author(s)

Effectiveness and safety of opicapone in Parkinson’s disease patients with motor fluctuations: the OPTIPARK open-label study

Background The efficacy and safety of opicapone, a once-daily catechol-O-methyltransferase inhibitor, have been established in two large randomized, placebo-controlled, multinational pivotal trials. Still, clinical evidence from routine practice is needed to complement the data from the pivotal trials. Methods OPTIPARK (NCT02847442) was a prospective, open-label, single-arm trial conducted in Germany and the UK under clinical practice conditions. Patients with Parkinson’s disease and motor fluctuations were treated with opicapone 50 mg for 3 (Germany) or 6 (UK) months in addition to their current levodopa and other antiparkinsonian treatments. The primary endpoint was the Clinician’s Global Impression of Change (CGI-C) after 3 months. Secondary assessments included Patient Global Impressions of Change (PGI-C), the Unified Parkinson’s Disease Rating Scale (UPDRS), Parkinson’s Disease Questionnaire (PDQ-8), and the Non-Motor Symptoms Scale (NMSS). Safety assessments included evaluation of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs). Results Of the 506 patients enrolled, 495 (97.8%) took at least one dose of opicapone. Of these, 393 (79.4%) patients completed 3 months of treatment. Overall, 71.3 and 76.9% of patients experienced any improvement on CGI-C and PGI-C after 3 months, respectively (full analysis set). At 6 months, for UK subgroup only (n = 95), 85.3% of patients were judged by investigators as improved since commencing treatment. UPDRS scores at 3 months showed statistically significant improvements in activities of daily living during OFF (mean ± SD change from baseline: − 3.0 ± 4.6, p < 0.0001) and motor scores during ON (− 4.6 ± 8.1, p < 0.0001). The mean ± SD improvements of − 3.4 ± 12.8 points for PDQ-8 and -6.8 ± 19.7 points for NMSS were statistically significant versus baseline (both p < 0.0001). Most of TEAEs (94.8% of events) were of mild or moderate intensity. TEAEs considered to be at least possibly related to opicapone were reported for 45.1% of patients, with dyskinesia (11.5%) and dry mouth (6.5%) being the most frequently reported. Serious TEAEs considered at least possibly related to opicapone were reported for 1.4% of patients. Conclusions Opicapone 50 mg was effective and generally well-tolerated in PD patients with motor fluctuations treated in clinical practice. Trial registration Registered in July 2016 at clinicaltrials.gov (NCT02847442)